肝肾综合征 中国就医指南

Hepatorenal syndrome (HRS) is a life-threatening functional renal failure that occurs in patients with advanced liver disease—most commonly decompensated cirrhosis or acute-on-chronic liver failure—without evidence of intrinsic kidney pathology. It is not caused by structural renal damage, obstruction, or nephrotoxic injury, but rather by profound systemic and splanchnic vasodilation, leading to intense renal vasoconstriction, reduced renal perfusion, and progressive decline in glomerular filtration rate (GFR). Two main types are recognized: Type 1 HRS, characterized by rapid deterioration in renal function (doubling of serum creatinine to >2.5 mg/dL or reduction in creatinine clearance by >50% to <20 mL/min within ≤2 weeks), and Type 2 HRS, marked by more gradual, stable but subnormal renal function (serum creatinine 1.5–2.5 mg/dL), often associated with refractory ascites. Pathogenesis centers on nitric oxide–mediated splanchnic arterial vasodilation, triggering activation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, and endothelin pathways—culminating in intense renal cortical vasoconstriction and impaired sodium/water excretion. Epidemiologically, HRS develops in approximately 10–20% of hospitalized patients with cirrhosis and ascites over one year; among those with spontaneous bacterial peritonitis (SBP), incidence rises to 30–40%. Risk factors include severe portal hypertension, low mean arterial pressure (<80 mmHg), hyponatremia (<130 mmol/L), high Child-Pugh or MELD scores, recent large-volume paracentesis without albumin infusion, and infections—especially SBP. HRS profoundly impairs quality of life: patients experience debilitating fatigue, anorexia, confusion (hepatic encephalopathy), dyspnea from fluid overload, and profound anxiety related to prognosis and treatment uncertainty. Without intervention, median survival for Type 1 HRS is less than 2 weeks; even with pharmacologic therapy, 3-month mortality exceeds 50%. The condition imposes substantial psychosocial burden—limiting mobility, disrupting employment and family roles, and necessitating frequent hospitalizations. Early recognition and multidisciplinary management involving hepatology, nephrology, and critical care are essential. While liver transplantation remains the only definitive cure, timely diagnosis and bridge therapies (e.g., terlipressin + albumin) can stabilize renal function and improve transplant candidacy. Patient education, nutritional support, and palliative integration are vital components of holistic care in advanced disease.

# 肝肾综合征（HRS）治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：HRS-1型（急性进展）或HRS-2型（慢性稳定）、肝功能Child-Pugh B/C级、未达肝移植指征者。

• •药物治疗（核心）：

- 米多君+奥曲肽替代方案：¥3,800–¥9,200；

• •支持治疗：限钠饮食、避免NSAIDs及肾毒性药、腹水穿刺放液（每次）：¥450–¥1,200；
• •检验检查费（基线+监测）：血肌酐、Cys-C、NGAL、肝肾功、动脉血气、超声心动图等：¥1,600–¥3,500。

二、介入与根治性方案

适用人群：HRS-1型经药物无效、MELD≥20、具备肝移植条件者。

• •经颈静脉肝内门体分流术（TIPS）：改善门脉高压，部分逆转HRS，¥68,000–¥115,000（含术前评估¥4,200、支架材料费¥35,000–¥72,000、术后监护¥8,000–¥15,000）；
• •肝移植（根治唯一手段）：¥350,000–¥620,000（含供体协调、手术、ICU、免疫抑制剂首年），术前评估（含肝肾MRI、心肺功能、感染筛查）：¥12,000–¥21,000。

三、特殊复杂情况处理

晚期肝衰竭合并多器官功能障碍、耐药性HRS或感染性休克：CRRT联合去甲肾上腺素维持灌注，¥18,000–¥45,000/周；肝肾联合移植罕见，费用超¥800,000。

方案快速选择指南

• •预算≤3万元：首选特利加压素+白蛋白保守治疗；
• •预算5–15万元且MELD 15–25：评估TIPS可行性；
• •MELD≥25或反复发作：启动肝移植评估，优先登记国家肝移植等待系统。